Issue: February 2013
January 23, 2013
2 min read
Save

New data highlight US hepatitis burden

Issue: February 2013

Recent data highlight the chronic viral hepatitis burden in the United States, especially among baby boomers. Patients aged 44 to 63 years comprised 50% of all hepatitis B virus infections and 75% of all hepatitis C virus infections.

Perspective from Anna Lok, MD

The Chronic Hepatitis Cohort Study was a prospective longitudinal, observational cohort study in which researchers reviewed the medical records of more than 1.6 million adults who were seen from 2006 to 2010. Among those, 2,202 had confirmed chronic HBV and 8,810 had confirmed chronic HCV.

In the cohort of patients with HBV infection, 57.8% were Asian/Pacific Islander, 28.3% were white and 13.3% were black. Most of the patients (76.3%) had private insurance, 16.5% had Medicare and 5.1% had Medicaid. From 2001 to 2010, 22.3% of patients had a liver biopsy, 37.9% were hospitalized at least once and 2.1% underwent liver transplant for end-stage liver disease. The death rate was 21.6 per 1,000 person-years

Among patients with HCV infection, 69.5% were white, 22.7% were black and 5.9% were Asian/Pacific Islander. Most of the patients (61.8%) had private insurance, 12.1% had Medicaid and 22.9% had Medicare. From 2001 to 2010, 38.4% of patients had a liver biopsy and 44.3% had been hospitalized at least once. In addition, 4.7% of patients underwent liver transplant for end-stage liver disease. The death rate was 33 per 1,000 person-years. In this cohort, 28% of patients had also been tested for HIV, of whom 2.9% were positive.

“[The Chronic Hepatitis Cohort Study] has already generated unique information about the high morbidity and mortality in this population,” the researchers wrote. “It is expected to yield much data-driven information about the impact of therapies, comorbidities and conditions on the general population with HBV and HCV in the future.”

The CDC recently recommended that all baby boomers, those born between 1945 and 1965, receive a one-time test for HCV.

Disclosure: The researchers report no relevant financial disclosures.